Tumor Inhibition by DepoVax-Based Cancer Vaccine Is Accompanied by Reduced Regulatory/Suppressor Cell Proliferation and Tumor Infiltration
Open Access
- 7 March 2013
- journal article
- research article
- Published by Wiley in ISRN Oncology
- Vol. 2013, 1-13
Abstract
A successful cancer vaccine needs to overcome the effects of immune-suppressor cells such as Treg lymphocytes, suppressive cytokine-secreting Tr1 cells, and myeloid-derived suppressor cells (MDSCs), while enhancing tumor-specific immune responses. Given the relative poor efficacy associated with current cancer vaccines, a novel vaccine platform called (DPX) was developed. C3 tumor-challenged mice were immunized with HPV-E7 peptide in DPX- or conventional-emulsion- (CE-) based vaccine. While control mice showed marked increase in Treg/MDSCs in spleen and blood, in mice treated with DPX-E7 the levels remained similar to tumor-free naive mice. Such differences were also seen within the tumor. Antigen-specific IL10-secreting CD4/CD8 T cells and TGF-β+CD8+ T cell frequencies were increased significantly in CE-treated and control mice in contrast to DPX-E7-immunized mice. Analysis of tumor-infiltrating cells revealed higher frequency of suppressor cells in untreated controls than in DPX-E7 group while the converse was true for tumor-infiltrating CD8 T cells. Immunization of tumor-bearing HLA-A2 transgenic mice with human vaccine DPX-0907, a peptide-based vaccine for breast/ovarian/prostate cancers, showed efficient induction of immune response to cancer peptides despite the presence of suppressor cells. Thus, this study provides the rationale for using DPX-based cancer vaccines in immune-suppressed cancer patients, to induce effective anticancer immunity.
Keywords
This publication has 38 references indexed in Scilit:
- The split nature of tumor-infiltrating leukocytesOncoImmunology, 2012
- In vivo suppressive function of myeloid‐derived suppressor cells is limited to the inflammatory siteEuropean Journal of Immunology, 2011
- Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccinesEuropean Journal of Cancer, 2010
- The tumor microenvironment and its role in promoting tumor growthOncogene, 2008
- Advances in tumour immunotherapyQJM: An International Journal of Medicine, 2008
- Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides VaccineClinical Cancer Research, 2008
- Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax®Journal of Translational Medicine, 2007
- Regulatory T cells in cancerBlood, 2006
- Effector Memory T Cells, Early Metastasis, and Survival in Colorectal CancerNew England Journal of Medicine, 2005
- Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.2001